![]() ![]() ![]() This provides the foundation for a prevention system of regionally prevalent cancers. ![]() We focus on prevention, and through provincial cancer screening programmes, have built comprehensive biobank and database for liver, gastric, colorectal and breast cancers. Launched in the 1930s, our oncology department is a national key clinical specialty. How will FAH’s anti-cancer strategies help ASEAN countries? The early diagnosis approach we proposed for the infection has been adopted by 50 institutions across China. We have also established molecular testing technologies for the infection, which were awarded a national invention patent. Working with the Imperial College London, we were the first to identify its epidemiological patterns. This is demonstrated in our diagnosis and treatment of southern China’s first reported case of entomophthoromycosis, a rare fungal infection that mimics various clinical entities.īreakthroughs have also been made in the research on a fungal disease endemic to Guangxi and Southeast Asia, Talaromyces marneffei infection, which can be life-threatening. We have created advanced platforms to incorporate multiple technologies for enhancing diagnosis of fungal infections. What technologies has FAH developed to control fungal diseases? ![]() Fully equipped with advanced facilities for various stem cell transplantation therapies, we have, to date, completed 750 transplants for thalassemia, achieving a cure rate of 93%, leading internationally. We have also devised preventive approaches to address transplant rejection and graft-versus-host disease. We pioneered using haematopoietic stem cell transplant to treat thalassemia in 1998, and led the way in using bone marrow, along with peripheral or umbilical cord blood as the source of stem cells. Our control technologies have been adopted across China, becoming a national model. Since the 1950s, we have established screening, genetic diagnosis, and prenatal diagnosis technologies for the prevention or control of thalassemia, significantly reducing thalassemia-related birth defects. Given its prevalence in Southeast Asia and southern China, our hospital was among the first nationally to start thalassemia research. Thalassemia is a hereditary blood disorder, which in its severe form has a high mortality rate, and is expensive to treat. What are FAH’s advantages in thalassemia control? By sharing our quality medical resources, we hope to contribute to a healthier partnership between China and ASEAN countries. In 2020, China and ASEAN countries became stronger trading partners, and in line with this trend, we launched the platform to serve the growing medical needs from ASEAN populations. We have also built close ties with many ASEAN countries through our long-term exchanges. Our hospital, as a provincial hub for medical research, education, and services, has established strengths in tackling these diseases, with an edge in medical talent, technologies, and experience. Those like Mediterranean anaemia (thalassemia), liver and nasopharyngeal cancers, and fungal infections are prevalent in the whole region, so we share similar needs in disease prevention and control. Aside from geographic proximity, Guangxi and ASEAN countries have similar disease spectrums. It’s a natural outcome given our geographic location, traditional strengths and experience, and the timing. Here, FAH’s president, Junqiang Chen, outlines his vision. Built on FAH’s established clinical strengths, the platform will improve medical accessibility in the region. Leveraging its gateway position, it is enhancing collaboration with countries in the Association of Southeast Asian Nations (ASEAN) by launching the China-ASEAN Cross-Border Medical Cooperation Platform. Junqiang Chen Credit: FAHFAH is a Class-A tertiary hospital in Nanning, the capital of southeast China’s Guangxi Province. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |